Share on StockTwits

Analysts at Credit Suisse cut their target price on shares of Pfizer (NYSE:PFE) from $35.00 to $34.00 in a research report issued to clients and investors on Thursday. Credit Suisse’s price target suggests a potential upside of 20.52% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at BMO Capital Markets downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating in a research note on Monday, July 28th. They now have a $31.00 price target on the stock, down previously from $34.00. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Pfizer in a research note on Monday, July 14th. They now have a $38.00 price target on the stock, up previously from $36.00. Finally, analysts at Barclays raised their price target on shares of Pfizer from $32.00 to $34.00 in a research note on Wednesday, July 2nd. They now have an “equal weight” rating on the stock. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $33.80.

Shares of Pfizer (NYSE:PFE) traded up 1.06% during mid-day trading on Thursday, hitting $28.51. 5,833,006 shares of the company’s stock traded hands. Pfizer has a 52-week low of $27.76 and a 52-week high of $32.96. The stock has a 50-day moving average of $29.66 and a 200-day moving average of $30.47. The company has a market cap of $180.8 billion and a price-to-earnings ratio of 17.72. Pfizer also was the target of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 72,619,112 shares, an increase of 19.2% from the July 15th total of 60,916,961 shares. Based on an average daily volume of 26,835,170 shares, the short-interest ratio is presently 2.7 days. Approximately 1.1% of the company’s stock are short sold.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 29th. The company reported $0.58 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.57 by $0.01. The company had revenue of $12.80 billion for the quarter, compared to the consensus estimate of $12.49 billion. During the same quarter last year, the company posted $0.56 earnings per share. Pfizer’s revenue was down 1.5% compared to the same quarter last year. On average, analysts predict that Pfizer will post $2.25 earnings per share for the current fiscal year.

Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.